Survodutide (BI 456906): GLP1/GCGR agonist | MASH Survodutide (BI 456906): GLP1/GCGR agonist | MASH Survodutide (BI 456906): GLP1/GCGR agonist | MASH
Vicadrostat (BI 690517) + empagliflozin Vicadrostat (BI 690517) + empagliflozin Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin Vicadrostat (BI 690517) + empagliflozin Vicadrostat (BI 690517) + empagliflozin
CHMP recommends new treatment for chronic kidney disease CHMP recommends new treatment for chronic kidney disease The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Galym Zhunisbekov Galym Zhunisbekov Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.
Survodutide (BI 456906): GLP1/GCGR agonist | obesity Survodutide (BI 456906): GLP1/GCGR agonist | obesity Survodutide (BI 456906): GLP1/GCGR agonist | obesity
Circular economy: Taking action to reduce plastic waste Circular economy: Taking action to reduce plastic waste The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
SPEVIGO approved expanded indications China US SPEVIGO approved expanded indications China US SPEVIGO® approved for expanded indications in China and the US
EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Pascal Haubert Pascal Haubert Three months into an internship with us, Pascal Haubert talks about responsibility, learning, and mutual support.
The Unwearable Collection™: Fashion Inspired by GPP The Unwearable Collection™: Fashion Inspired by GPP An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
CT-155: Prescription digital therapeutic CT-155: Prescription digital therapeutic CT-155: Prescription digital therapeutic
Making a difference with data science Making a difference with data science Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
SPEVIGO CHMP positive opinion new indications SPEVIGO CHMP positive opinion new indications CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Cristian Torreblanca Cristian Torreblanca Cristian Torreblanca Estrada is a Corporate Global Facilities and Engineering Senior Manager Controller in Germany – with plans for growth across the global business.
Dirk Stenkamp Dirk Stenkamp Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.